<DOC>
	<DOCNO>NCT01443104</DOCNO>
	<brief_summary>Coronary artery stent improve safety efficacy percutaneous coronary intervention coronary artery disease . Drug-eluting stent show decrease neointimal hyperplasia reduce rate restenosis target-lesion revascularization compare bare-metal stent . Drug-eluting stent consist metallic platform therapeutic substance usually release polymer matrix . A previous study utilize bioresorbable polymer demonstrate favorable safety efficacy profile large-scale clinical trial compare first-generation druf-eluting stent ( LEADERS trial ) . The objective study compare safety efficacy sirolimus-eluting stent biodegradable polymer everolimus-eluting stent durable polymer prospective multicenter randomize control non-inferiority trial patient undergo percutaneous coronary intervention routine clinical practice .</brief_summary>
	<brief_title>Sirolimus-eluting Stents With Biodegradable Polymer Versus Everolimus-eluting Stents</brief_title>
	<detailed_description>Background Coronary artery stent improve safety efficacy percutaneous coronary intervention compare balloon angioplasty alone ( New Engl J Med 1994 ; 331:489-495 ) . Notwithstanding , restenosis still encounter 20 30 % lesion implantation bare metal stent ( JAMA 2000 ; 284:1828-36 ) may require repeat revascularization procedure negative impact quality life health care expenditures . Drug-eluting stent local , control release therapeutic agent address problem successfully ( Circulation 2003 ; 107:3003-7 ) . Current drug-eluting stent consist metallic stent platform therapeutic agent , either directly immobilize stent surface release polymer matrix . Polymers currently utilized drug-eluting stent either biodegradable non-biodegradable . While biodegradable polymer release together drug dissolve certain period time , non-biodegradable polymer reside permanently stent surface . First-generation drug-eluting stent utilized sirolimus paclitaxel prevention restenosis . Both drug highly lipophilic show rapid strong uptake arterial wall tissue . In addition , Sirolimus ( Circulation 2001 ; 104:852-5 ) paclitaxel ( Circulation 1997 ; 96:636-45 ) show reduce smooth muscle cell proliferation neointimal hyperplasia , principal cause restenosis coronary stenting experimental model . A polymer-encapsulated stent release Sirolimus compare respective bare metal stent several randomize clinical trial , demonstrate consistent reduction angiographic clinical restenosis ( N Engl J Med 2002 ; 346:1773-80 ) . Similarly , polymer-based , paclitaxel-eluting stent consistently reduce restenosis need repeat revascularization procedure compare respective bare metal stent ( N Engl J Med 2004 ; 350:221-31 ) . A meta-analysis drug-eluting stent trial confirm reduction restenosis repeat revascularization procedures polymer-based , drug-eluting stent ( Lancet 2004 ; 364:583-91 ) . Moreover , rate death myocardial infarction comparable bare metal stent , attest safety device , approve US Food Drug Administration . Newer generation drug-eluting stent durable polymer coat utilize Limus analogue everolimus , zotarolimus novolimus . Everolimus-eluting stent compare first-generation drug-eluting stent several randomized clinical trial . A pooled analysis four large randomize trial date compare everolimus-eluting stent paclitaxel-eluting stent demonstrate low rate MACE ( 4.4 % versus 7.6 % ) , myocardial infarction ( 2.1 % vs. 4.0 % , p &lt; 0.001 ) , ischemic TLR ( 2.3 % vs. 4.7 % , p &lt; 0.001 ) , definite stent thrombosis ( 0.4 % vs. 1.2 % , p &lt; 0.001 ) favor EES , whereas difference regard overall cardiac mortality ( Stone GW . The XIENCE V - PROMUS Everolimus-Eluting Stent : New Insights SPIRIT/COMPARE Meta-analysis randomized trial . Presentation Transcatheter Cardiovascular Therapeutics , September 22nd 2010 ) . At time several trial compare everolimus-eluting stent sirolimus-eluting stent report favorable performance everolimus-eluting stent . In randomized trial enrol 2'774 patient everolimus-eluting stent non-inferior compare sirolimus-eluting stent nine month regard MACE ( 4.9 % vs. 5.2 % , HR 0.94 , 0.67-1.31 ) TLR ( 1.4 % vs. 1.7 % , HR 0.87 , 0.48-1.58 ) ( N Engl J Med 2010 ; 362 ( 28 ) :1663-74 ) . Likewise , event rate two year similar everolimus-eluting stent sirolimus-eluting stent ( 3.7 % versus 4.3 % , p=0.85 ) randomize control trial compare EES , SES , BMS large vessel ( stent diameter &gt; 3.0 mm ) , whereas TVR low EES ( 3.7 % ) SES ( 4.3 % ) compare bare-metal stent ( 10.3 % , P=0.005 v SES , P=0.002 v EES ) ( N Engl J Med 2010 ; 363 ( 24 ) :2310-9 ) . A propensity-score matched comparison EES SES report low event rate myocardial infarction ( 3.3 % versus 5.0 % , HR 0.62 , 95 % CI 0.42-0.92 , P=0.017 ) part due low risk stent thrombosis ( definite probable 2.5 % versus 4.0 % , HR 0.64 , 95 % CI 0.41-0.98 , P=0.041 ) , well low rate target vessel revascularization ( 7.0 % versus 9.6 % , HR 0.75 , 95 % CI 0.57-0.99 , P=0.039 ) EES three year mortality similar ( Windecker S. Long-term comparison Everolimus-eluting Sirolimus-eluting Stents coronary revascularization 1 ( LESSON1 ) study . Presentation European Society Cardiology meeting , Stockholm , Sweden , 31st August 2010 . 2010 ) . A previous study utilize bioresorbable polymer demonstrate favorable safety efficacy profile large-scale clinical trial compare first-generation drug-eluting stent . Among 1,707 patient randomize either biolimus-eluting stent bioresorbable polymer sirolimus-eluting stent durable polymer significant difference regard primary endpoint cardiac death , myocardial infarction target-vessel revascularization observe ( 9.2 % versus 10.5 % , HR 0.88 , 95 % CI 0.64-1.19 ; : p=0.39 ) ( Lancet 2008 ; 372:1163-73 . ) Objective The objective study compare safety efficacy sirolimus-eluting stent biodegradable polymer everolimus-eluting stent durable polymer prospective multicenter randomize control non-inferiority trial patient undergo percutaneous coronary intervention routine clinical practice . Methods Design : Prospective , multi-center , randomize , non-inferiority trial . Patients randomize single-blind fashion ( 1:1 randomization ) either Orsiro® Stent system ( Sirolimus-eluting stent biodegradable polymer ) Xience PRIME® stent system ( Everolimus-eluting stent durable polymer ) . Primary endpoint : Target lesion failure ( TLF ) , define composite cardiac death , target vessel myocardial infarction ( MI ) , clinically drive target-lesion revascularization ( TLR ) . Inclusion Criteria : `` Real world , comer '' patient symptomatic coronary artery disease include patient chronic stable angina , silent ischemia , acute coronary syndrome include NSTE-ACS STE-ACS , presence one coronary artery stenoses &gt; 50 % native coronary artery saphenous bypass graft treat stent range diameter 2.25 4.0 mm cover one multiple stent .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age ≥18 year Symptomatic coronary artery disease include patient chronic stable angina , silent ischemia , acute coronary syndrome include NSTEACS STEACS Presence one coronary artery stenoses &gt; 50 % native coronary artery saphenous bypass graft treat stent range diameter 2.25 4.0 mm cover one multiple stents No limitation number treat lesion , vessel , lesion length Exclusion Criteria Pregnancy Known intolerance aspirin , clopidogrel , heparin , stainless steel , Sirolimus , Everolimus contrast material Inability provide inform consent Currently participate another trial reach first endpoint Planned surgery within 6 month PCI unless dual antiplatelet therapy maintain throughout perisurgical period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>drug-eluting stent</keyword>
	<keyword>polymer</keyword>
</DOC>